Despite the competitive nature for funding in the crowded weight loss treatment space, Metsera has won $215m to advance its glucagon-like peptide-1 receptor agonist (GLP-1RA) orientated portfolio.

If any further evidence were needed for the insatiable investor appetite for companies with obesity assets, look no further than New York start-up Metsera. After emerging from stealth with a $290 ...

Structure Therapeutics (GPCR) stock and Metsera (MTSR) stock soar as Eli Lilly (LLY) reports promising Phase 3 results for ...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is being studied in multiple Phase 2b clinical trials with read-outs beginning mid-2025 Multiple data readouts in mid ...

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to ...

Based on current operating plans, Metsera (MTSR) estimates its existing cash and cash equivalents of $352.4 at year end, together with the net proceeds from the IPO, will be sufficient to fund our ...

Shares of up-and-coming weight loss drug developers Viking Therapeutics (NASDAQ:VKTX), Metsera (NASDAQ:MTSR), and Structure Therapeutics (NASDAQ:GPCR) traded sharply higher after Pfizer (NYSE ...

We expect 2025 to be another year of execution and growth, as we rapidly advance Metsera’s portfolio of ultra-long acting, scalable and combinable injectable and oral candidates.” Pipeline ...

In this article, we are going to take a look at where Metsera, Inc. (NASDAQ:MTSR) stands against other top insider purchases last month. Will there be a recession? How will new tariffs impact the ...

“2024 was a year of exceptional execution and acceleration at Metsera,” said Whit Bernard, Chief Executive Officer of Metsera.“We advanced MET-097i, our monthly, fully-biased GLP-1 RA ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...